Sylvie Trottier
| Sylvie Trottier | |
|---|---|
| Born | May 20, 1952 Quebec City, Canada |
| 🎓 Alma mater | Laval University (BSc & MSc) University of Göteborg (Fellow, Infectious Diseases) |
| 💼 Occupation | |
| Known for | Clinical research in infectious diseases, HIV/AIDS and comorbidities, HPV, vaccines, Infection prevention and control in healthcare settings. |
Sylvie Trottier is a Canadian physician and a medical researcher specializing in infectious diseases, particularly HIV/AIDS. She is recognized for her contributions to clinical research in infectious diseases and for her patient-centered approach to clinical care.
Education
Trottier earned two undergraduate degrees from Laval University, a Bachelor of Science in Microbiology in 1975 and a Bachelor of Science in Biochemistry in 1976. She went on to complete a Master's degree in Medical Microbiology in 1978 under the supervision of Dr. Michel G. Bergeron.
She pursued her medical degree at McGill University, graduating with an MDCM in 1982. Driven by a growing interest in infectious diseases, she returned to Laval University to complete a residency in infectious diseases, finishing her training in 1985.
In 1985, Trottier undertook postdoctoral training at the University of Göteborg in Sweden, where she worked with Dr. Catharina Svanborg-Edén on mucosal immunity and bacterial pathogenesis. She studied germ transmission in daycare settings, revealing that harmless Haemophilus influenzae strains exhibited distinct colonization patterns: some persisted in individuals for weeks, while others spread rapidly among children without establishing long-term carriage.[1]
Career
Trottier began her medical and academic career at the Québec Heart and Lung Institute (IUCPQ) and at the CHU de Québec – Université Laval (CHUL) in 1986, joining the institution at a time when the HIV/AIDS pandemic was emerging. She became rapidly involved in the care of people living with HIV and has remained at the forefront of both clinical practice and medical research related to HIV/AIDS and other infectious diseases.
In 1995, she was appointed Chief of Clinical Research at the Infectious Disease Research Centre (Centre de recherche en infectiologie, CRI) of Laval University. That same year, she also became the director of the "Unité hospitalière de recherche, d'enseignement et de soins sur le sida" (UHRESS) at CHUL, a multidisciplinary HIV/AIDS clinic, which serves as a major referral center for patients from across Eastern Quebec. This unit combines clinical care, research, and teaching with a holistic approach to treating individuals living with HIV/AIDS.
Trottier served (1999-2015) as the Director of the Clinical Laboratories at the Québec Heart and Lung Institute (IUCPQ).
She also served (2011-2019) as the Director of the Department of "Microbiologie-Infectiologie et Immunologie" of the Faculty of Medicine, Laval University.
COVID-19 Pandemic
During the COVID-19 pandemic, Dr. Trottier and her team studied the immune response to SARS-CoV-2 in at-risk essential workers.[2][3]
Contributions and Impact
Throughout her career that spanned almost five decades, Trottier has been recognized for bridging clinical care and research in infectious diseases. She has contributed to numerous studies on HIV, while advocating for compassionate, long-term care models tailored to the needs of vulnerable populations through her UHRESS clinic as a model.
Trottier has been a leading figure in the development of integrated care models for chronic infectious diseases, blending clinical care, research, teaching and public health. Her work has improved patient outcome, advanced innovative prevention strategies, and contributed to real-world approaches for managing HIV, herpes, influenza and emerging infections through innovative diagnosis, treatment and prevention. As both a scientist and a clinician, she exemplifies a form of leadership that strengthens the entire continuum of care. Over the course of her clinical and scientific career, Trottier has led over 380 clinical trials across HIV, influenza, herpes, HPV, Zika, COVID-19, EV-D68 and other infectious diseases.[4] Dr. Trottier’s work generated more than 9,000 citations and continues to have a strong impact, with over 500 citations annually.[5] She has shaped translational and clinical research at Université Laval and contributed to landmark international studies (SMART, Reprieve).[6] Trottier’s publications reflect the breadth and impact of her research, including her role as a clinical investigator in major international trials that led to innovative diagnostic tools, antiviral medications, and vaccines that have improved and saved thousands of lives over the past five decades.
Awards and honors
- 2008 - Farha Foundation Award « Hommage aux Héros » in recognition of 20 years of fighting HIV/AIDS and caring for patients.[7]
- 2019 - Laureate of the Council of physicians, dentists and pharmacists (CMDP of IUCPQ) category « Qualité de l’acte » (Best in Patients’ Safety).
- 2023 - CHU de Quebec Research Center Awards “Prix Découverte” - Best Collaborative Group.[8]
- 2025 - CHU de Québec Research Center Awards "Prix Recherche-Carrière".[9]
References
- ↑ Trottier, S; Stenberg, K; Svanborg-Edén, C (October 1989). "Turnover of nontypable Haemophilus influenzae in the nasopharynges of healthy children". Journal of Clinical Microbiology. 27 (10): 2175–2179. doi:10.1128/jcm.27.10.2175-2179.1989. PMC 266988. PMID 2584370.
- ↑ ICI.Radio-Canada.ca, Zone Santé- (2021-06-14). "Étude sur la COVID-19 chez les travailleurs du secteur du détail". Radio-Canada (in français). Retrieved 2025-04-14.
- ↑ Santerre, Kim; Thériault, Mathieu; Brousseau, Nicholas; Langlois, Marc-André; Arnold, Corey; Pelletier, Joelle N.; Gilbert, Caroline; Masson, Jean-François; Baz, Mariana; Boudreau, Denis; Trottier, Sylvie (2024-12-16). "Infection Rate and Risk Factors of SARS-CoV-2 Infection in Retail Workers at the Onset of the COVID-19 Pandemic, Quebec, Canada". Infectious Disease Reports. 16 (6): 1240–1253. doi:10.3390/idr16060098. ISSN 2036-7449. PMC 11675805 Check
|pmc=value (help). PMID 39728020 Check|pmid=value (help). - ↑ Tebas, Pablo; Roberts, Christine C.; Muthumani, Kar; Reuschel, Emma L.; Kudchodkar, Sagar B.; Zaidi, Faraz I.; White, Scott; Khan, Amir S.; Racine, Trina; Choi, Hyeree; Boyer, Jean; Park, Young K.; Trottier, Sylvie; Remigio, Celine; Krieger, Diane (2021-09-16). "Safety and Immunogenicity of an Anti–Zika Virus DNA Vaccine". New England Journal of Medicine. 385 (12): e35. doi:10.1056/NEJMoa1708120. ISSN 0028-4793. PMC 6824915 Check
|pmc=value (help). PMID 34525286 Check|pmid=value (help). - ↑ "Sylvie Trottier". scholar.google.com. Retrieved 2025-11-22.
- ↑ The Strategies for Management of Antiretroviral Therapy (SMART) Study Group (2008-04-15). "Major Clinical Outcomes in Antiretroviral Therapy (ART)–Naive Participants and in Those Not Receiving ART at Baseline in the SMART Study". The Journal of Infectious Diseases. 197 (8): 1133–1144. doi:10.1086/586713. ISSN 0022-1899. PMID 18476292.
- ↑ "The Farha Foundation's seventh annual HEROES NIGHT | Positively Positive". www.positivelypositive.ca. Retrieved 2025-04-14.
- ↑ Média, Boréale; cri-laval (2022-05-26). "First edition of the Centre de recherche du CHU de Québec - Université Laval "Prix Découverte" Awards - Two wins for IDRC researchers". Centre de recherche en infectiologie. Retrieved 2025-04-14.
- ↑ "Prix Recherche | CHU de Québec-Université Laval". www.chudequebec.ca (in français). Retrieved 2025-11-22.
See also
This article "Sylvie Trottier" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Sylvie Trottier. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
